Therapy Name | BAY1834942 |
Therapy Description |
BAY1834942 is a monoclonal antibody against CEACAM6 that blocks downstream signaling, resulting in enhanced T-cell response (Cancer Res 2018;78(13 Suppl):Abstract nr 1771). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY1834942 | BAY1834942 is a monoclonal antibody against CEACAM6 that blocks downstream signaling, resulting in enhanced T-cell response (Cancer Res 2018;78(13 Suppl):Abstract nr 1771). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Recruiting |